Literature DB >> 1697324

Topological mapping of the P1-adhesin of Mycoplasma pneumoniae with adherence-inhibiting monoclonal antibodies.

B Gerstenecker1, E Jacobs.   

Abstract

Five adherence-inhibiting monoclonal antibodies (mAbs) were used for topological mapping of the binding sites of the 169 kDa membrane-integrated adhesin of Mycoplasma pneumoniae. Antibody binding sites were characterized using overlapping synthetic octapeptides. Three regions of the protein seem to be involved in adherence: the N-terminal region [N-reg, epitopes beginning at amino acid (aa) 1 to aa 14 and aa 231 to aa 238, respectively]; a domain (D1) approximately in the middle of the molecule (beginning at aa 851 to aa 858 and aa 921 to aa 928); and a domain (D2) closer to the C-terminus (beginning at aa 1303 to aa 1310, aa 1391 to aa 1398 and aa 1407 to aa 1414). Each of the mAbs P1.26 and P1.62 reacted with two primary amino acid sequences. Both antibodies bound to the D1 region, but mAb P1.62 showed additional binding to a sequence (aa 231 to aa 238) near the N-terminus, and mAb P1.26 reacted with a second epitope in the D2 domain (aa 1303 to aa 1310). Such dual binding by the two antibodies suggests that in the native protein the epitopes are composed of two sequences which are located on two different sites of the molecule (D1/N-reg and D1/D2, respectively).(ABSTRACT TRUNCATED AT 250 WORDS)

Mesh:

Substances:

Year:  1990        PMID: 1697324     DOI: 10.1099/00221287-136-3-471

Source DB:  PubMed          Journal:  J Gen Microbiol        ISSN: 0022-1287


  21 in total

1.  Identification of a new variable sequence in the P1 cytadhesin gene of Mycoplasma pneumoniae: evidence for the generation of antigenic variation by DNA recombination between repetitive sequences.

Authors:  T Kenri; R Taniguchi; Y Sasaki; N Okazaki; M Narita; K Izumikawa; M Umetsu; T Sasaki
Journal:  Infect Immun       Date:  1999-09       Impact factor: 3.441

2.  Mycoplasma pneumoniae P1 type 1- and type 2-specific sequences within the P1 cytadhesin gene of individual strains.

Authors:  J W Dorigo-Zetsma; B Wilbrink; J Dankert; S A Zaat
Journal:  Infect Immun       Date:  2001-09       Impact factor: 3.441

3.  GapA and CrmA coexpression is essential for Mycoplasma gallisepticum cytadherence and virulence.

Authors:  L Papazisi; S Frasca; M Gladd; X Liao; D Yogev; S J Geary
Journal:  Infect Immun       Date:  2002-12       Impact factor: 3.441

4.  Loss of co-chaperone TopJ impacts adhesin P1 presentation and terminal organelle maturation in Mycoplasma pneumoniae.

Authors:  Jason M Cloward; Duncan C Krause
Journal:  Mol Microbiol       Date:  2011-06-23       Impact factor: 3.501

5.  Isolation and characterization of P1 adhesin, a leg protein of the gliding bacterium Mycoplasma pneumoniae.

Authors:  Daisuke Nakane; Jun Adan-Kubo; Tsuyoshi Kenri; Makoto Miyata
Journal:  J Bacteriol       Date:  2010-11-19       Impact factor: 3.490

6.  A B cell-, T cell-linked epitope located on the adhesin of Mycoplasma pneumoniae.

Authors:  E Jacobs; R Röck; L Dalehite
Journal:  Infect Immun       Date:  1990-08       Impact factor: 3.441

7.  Identification of the cilium binding epitope of the Mycoplasma hyopneumoniae P97 adhesin.

Authors:  T Hsu; F C Minion
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

8.  Cloning and functional analysis of the P97 swine cilium adhesin gene of Mycoplasma hyopneumoniae.

Authors:  T Hsu; S Artiushin; F C Minion
Journal:  J Bacteriol       Date:  1997-02       Impact factor: 3.490

9.  Are outbreaks and sporadic respiratory infections by Mycoplasma pneumoniae due to two distinct subtypes?

Authors:  E Jacobs; M Vonski; K Oberle; O Opitz; K Pietsch
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-01       Impact factor: 3.267

10.  Mycoplasma pneumoniae protein P30 is required for cytadherence and associated with proper cell development.

Authors:  C E Romero-Arroyo; J Jordan; S J Peacock; M J Willby; M A Farmer; D C Krause
Journal:  J Bacteriol       Date:  1999-02       Impact factor: 3.490

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.